Cancer Clinical Trials

When the way forward isn’t clear…

Maybe a clinical trial is right for you.

If you or a loved one has cancer and the current treatment option isn’t working, a clinical trial might be right for you. Clinical trials offer the latest therapy to improve on the standard of care and to test how new medical approaches work when other methods have failed. Clinical treatments have resulted in new treatments and prevention options for cancer care.

Participation in a cancer clinical trial also offers more interactive, precise and personalized care for you. Your treatment team is broader, coming from a range of disciplines. This allows more individualized attention to your care. A Phase I clinical trial can also allow you to stay closer to your home setting without having to travel to another destination.

If you are interested in learning more about a clinical trial, complete the form below or call (864) 920-2523. (This number is answered Monday through Friday, 8:30 a.m. to 5 p.m.  Please leave a voice message after business hours and your call will be returned within two business days.)

View below all of our active clinical trials.

Request Information on Clinical Trials

Someone will contact you within two business days.

How May We Help You?

Contact us: (864) 920-2523

Monday through Friday, 8:30 a.m. to 5 p.m.
or leave a message after business hours if you need active treatment for cancer. These trials do not pay you for participation.

Learn more about Clinical Trials

Learn more about clinical trials supported by National Cancer Institute (NCI) in this brief video.

Clinical Trials Available

Current Clinical Trials

Disease SiteStudyLocation
Disease Site: Supportive Care

URCC 18007   View on ClinicalTrials.gov
Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue

OP Cancer Institute Research
864-241-6251
Disease Site: Solid Tumors

Compass CTX-471-001   View on ClinicalTrials.gov
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

ITOR
864-455-3600
Disease Site: Supportive Care

WFU 1802   View on ClinicalTrials.gov
Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

OP Cancer Institute Research
864-241-6251
Disease Site: Gastric/GE Junction

Astellas 8951-CL-0302   View on ClinicalTrials.gov
A Phase 3, Global, Multi-Center, Double-Blind, Randomized,Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

OP Cancer Institute Research
864-241-6251
Disease Site: Lymphoma

USO 18104   View on ClinicalTrials.gov
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (017007)

OP Cancer Institute Research
864-241-6251
Disease Site: Breast

SWOG S1706   View on ClinicalTrials.gov
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

OP Cancer Institute Research
864-241-6251
Disease Site: Pancreatic

CTSU EA2161   View on ClinicalTrials.gov
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) plan to open with CIRB when patient identified

OP Cancer Institute Research
864-241-6251
Disease Site: Lymphoma

USO 16065/TG Therapeutics UTX-TGR-205   View on ClinicalTrials.gov
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

OP Cancer Institute Research
864-241-6251
Disease Site: Thymic

SWOG S1701   View on ClinicalTrials.gov
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

OP Cancer Institute Research
864-241-6251
Disease Site: Renal

CTSU EA8143   View on ClinicalTrials.gov
Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with localized Renal Cell Carcinoma Undergoing Nephrectomy

OP Cancer Institute Research
864-241-6251